{"schema_version":"secwatch.filing_event.v1","accession":"0001534969-26-000035","form_type":"8-K","ticker":"SERA","cik":"0001534969","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2026-06-30T20:09:46+00:00","discovered_at":"2026-06-30T20:11:00.275284+00:00","generated_at":"2026-06-30T20:11:14.314225+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Sera Prognostics appoints Mark Capone to Board of Directors effective July 1, 2026","bullets":["Mark Capone appointed as Class II director effective July 1, 2026, and to the Compensation Committee.","Capone is former CEO of Myriad Genetics with 40+ years in diagnostics and life sciences.","Initial equity award of $167,072 (or 150,000 option equivalents) granted July 10, 2026, with multi-year vesting.","Annual equity awards of $88,359 (or 75,000 option equivalents) after each annual meeting, vesting over one year.","Board determined Capone is independent under Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-26-000035","json":"https://secwatch.observer/filing/0001534969-26-000035.json","markdown":"https://secwatch.observer/filing/0001534969-26-000035.md","text":"https://secwatch.observer/filing/0001534969-26-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000035/0001534969-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000035/sera-20260625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T20:11:14.314225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}